pp-277 Solution for injection/infusion
Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Hematological disease, Immune disorder, Gastrointestinal disease
Clinical stage: Phase 2
Modality: RNA therapeutic
Mechanism & Target: Genetic modulator, Pathway modulator, Gene target
Route & form: SC injection / IV infusion
Differentiation: A best-in-class potential complement factor B (CFB) - targeting siRNA therapeutic for Paroxysmal Nocturnal Hemoglobinuria (PNH) in Ph2/3 stage. Complement-mediated kidney diseases (IgAN, Lupus Nephritis, C3G, IC-MPGN) in Ph2 stage
Manufacturer #39686
A clinical-stage biopharmaceutical company focused on immunology / inflammatory diseases. Developing a RNA-based therapeutic targeting immunology / inflammatory diseases with global development focus. Pipeline positioned for regulatory advancement in key markets.
None